GLENMARK PHARMACEUTICALS
Quarterly Results Analysis [Dec2023]
GLENMARK PHARMACEUTICALS Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 Audited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 Audited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹2,507 Cr | ₹3,207 Cr | ₹3,402 Cr | ₹3,374 Cr | ₹3,100 Cr | ₹3,018 Cr | ₹2,777 Cr | ₹3,019 Cr |
Expenses | ₹2,715 Cr | ₹2,745 Cr | ₹2,770 Cr | ₹2,769 Cr | ₹2,626 Cr | ₹2,539 Cr | ₹2,346 Cr | ₹2,556 Cr |
Operating Income | ₹-209 Cr | ₹462 Cr | ₹631 Cr | ₹605 Cr | ₹474 Cr | ₹479 Cr | ₹432 Cr | ₹463 Cr |
Other Income | ₹45 Cr | ₹2 Cr | ₹21 Cr | ₹-40 Cr | ₹71 Cr | ₹86 Cr | ₹183 Cr | ₹107 Cr |
Interest | ₹134 Cr | ₹121 Cr | ₹112 Cr | ₹109 Cr | ₹97 Cr | ₹83 Cr | ₹60 Cr | ₹87 Cr |
Depreciation | ₹147 Cr | ₹141 Cr | ₹155 Cr | ₹147 Cr | ₹152 Cr | ₹146 Cr | ₹147 Cr | ₹132 Cr |
Profit Before Tax | ₹-521 Cr | ₹-124 Cr | ₹333 Cr | ₹-491 Cr | ₹330 Cr | ₹337 Cr | ₹408 Cr | ₹270 Cr |
Profit After Tax | ₹-450 Cr | ₹-180 Cr | ₹173 Cr | ₹-403 Cr | ₹186 Cr | ₹172 Cr | ₹211 Cr | ₹173 Cr |
EPS | ₹-12.45 | ₹-2.90 | ₹5.31 | ₹-15.18 | ₹9.66 | ₹9.23 | ₹6.82 | ₹5.51 |
Industry Peers & Returns | 1W | 1M | 1Y |
GLENMARK PHARMACEUTICALS | 4% | 6.2% | 118% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
GLENMARK PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -21.85 % |
Y-o-Y | -19.14 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹2,507 Cr | -21.85 | |
Sep2023 | ₹3,207 Cr | -5.71 | |
Jun2023 | ₹3,402 Cr | 0.83 | |
Mar2023 | ₹3,374 Cr | 8.82 | |
Dec2022 | ₹3,100 Cr | 2.73 | |
Sep2022 | ₹3,018 Cr | 8.66 | |
Jun2022 | ₹2,777 Cr | -8.01 | |
Mar2022 | ₹3,019 Cr | - |
GLENMARK PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹-209 Cr | Negative | |
Sep2023 | ₹462 Cr | -26.76 | |
Jun2023 | ₹631 Cr | 4.34 | |
Mar2023 | ₹605 Cr | 27.62 | |
Dec2022 | ₹474 Cr | -1.03 | |
Sep2022 | ₹479 Cr | 10.98 | |
Jun2022 | ₹432 Cr | -6.86 | |
Mar2022 | ₹463 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | -8.32% | Negative | |
Sep2023 | 14.41% | -22.36 | |
Jun2023 | 18.56% | 3.51 | |
Mar2023 | 17.93% | 17.27 | |
Dec2022 | 15.29% | -3.65 | |
Sep2022 | 15.87% | 2.12 | |
Jun2022 | 15.54% | 1.24 | |
Mar2022 | 15.35% | - |
GLENMARK PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹-450 Cr | Negative | |
Sep2023 | ₹-180 Cr | Negative | |
Jun2023 | ₹173 Cr | Positive | |
Mar2023 | ₹-403 Cr | Negative | |
Dec2022 | ₹186 Cr | 8.14 | |
Sep2022 | ₹172 Cr | -18.62 | |
Jun2022 | ₹211 Cr | 22.33 | |
Mar2022 | ₹173 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | -17.94 % | Negative | |
Sep2023 | -5.62 % | Negative | |
Jun2023 | 5.09 % | Positive | |
Mar2023 | -11.95 % | Negative | |
Dec2022 | 5.99 % | 5.27 | |
Sep2022 | 5.69 % | -25.13 | |
Jun2022 | 7.6 % | 32.87 | |
Mar2022 | 5.72 % | - |
GLENMARK PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹-12.45 | Negative | |
Sep2023 | ₹-2.9 | Negative | |
Jun2023 | ₹5.31 | Positive | |
Mar2023 | ₹-15.18 | Negative | |
Dec2022 | ₹9.66 | 4.66 | |
Sep2022 | ₹9.23 | 35.34 | |
Jun2022 | ₹6.82 | 23.77 | |
Mar2022 | ₹5.51 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD